抗TIGIT药物Domvanalimab联合抗PD-1药物Zimberelimab及化疗作为不可切除或晚期胃食管腺癌一线治疗在2期Edge-Gastric研究中显示26.7个月中位总生存期
抗TIGIT药物Domvanalimab联合抗PD-1药物Zimberelimab及化疗作为不可切除或晚期胃食管腺癌一线治疗在2期Edge-Gastric研究中显示26.7个月中位总生存期
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.